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The mixed tumor lymphocyte culture (MTLC) 1 has been reported as being an 
effective in vitro means of generating  lymphocytes cytotoxic to leukemia cells 
(1). The cytotoxic capabilities of cells harvested from MTLC reactions have been 
demonstrated in lymphocyte-mediated cytolysis (LMC) assays (2), and the reac- 
tivities of these lymphocytes have corresponded with in vitro cytotoxicities of 
lymphocytes harvested from tumor-immune animals  (3) as well as with in vivo 
transplantation resistance (4). However, the MTLC-LMC system has only corre- 
sponded with tumor immunity studies of highly antigenic systems. MTLC have 
succeeded in generating  cytotoxic lymphocytes from normal  lymphoid popula- 
tions  (5)  and  have  enhanced  the  cytotoxicity of cells harvested  from  tumor- 
immune animals (6). This has only been possible when the tumor cell used was 
capable  of generating  an  eventually  regressing  tumor  in  vivo.  Lymphocytes 
harvested from mice with progressively growing tumors have been incapable of 
being stimulated  via MTLC to display in vitro cytotoxicity against  syngeneic 
tumor cell targets  (5, 6). 
Early  investigation  showed that  leukemias  induced by different  strains  of 
murine  leukemia  virus  (MuLV)  were cross-reactive  in their  ability to confer 
syngeneic tumor transplantation  resistance  (7).  Virus-induced  leukemia cells 
were shown to share  serologically defined cross-reactive antigens with alloge- 
neic leukemia cells induced by the same virus (8). Furthermore,  immunization 
with allogeneic leukemia cells was often more effective in conferring syngeneic 
tumor transplantation  immunity than was immunization with syngeneic tumor 
cells (9). Because in many cases, high immunizing concentrations of allogeneic 
leukemia  cells  were  utilized,  allogeneic  immunization  might  have  evoked a 
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more  effective immunity  because  allogeneic  cells presented  a  greater  tumor 
antigen  load or because they displayed histoincompatible antigens which pro- 
vided an allogeneic effect. 
Transplantation  resistance  demonstrated in these early studies was always 
conferred  by immunization  with  syngeneic  or  allogeneic cells which  actively 
produced  infectious  MuLV.  More  recently,  virus-producing  tumor  cells  have 
been shown to express viral structural proteins and glycoprotein (10) at the cell 
surface.  These viral polypeptides are capable of evoking a  detectable immune 
response in heterologous or homologous species (11,  12). Viral antigens may be 
partially  responsible  for  the  anti-tumor  immunity  demonstrated  in  in  vivo 
transplantation  resistance experiments to virus-producing cells. 
Because human  leukemia  cells have not been demonstrated  to be effective 
producers of C-type RNA tumor virus nor to express viral proteins at the cell 
surface,  we  have  focused  our  attention  on  nonvirus  producing  tumor  cells 
(nonproducers).  Recent  studies  have  concluded  that  nonproducers  are  more 
tumorigenic and less antigenic than virus-producing leukemia cell lines (13) and 
attempts  to  demonstrate  in  vivo tumor-specific  transplantation  resistance  to 
nonproducers have been difficult (14). 
Since allogeneic leukemia cells were effective generators of in vivo syngeneic 
tumor immunity,  we have attempted to use allogeneic nonproducer  leukemia 
cells  in  vitro  to  generate  tumor-specific  cytotoxic  lymphocytes.  This  report 
describes how repetitive MTLC stimulation of normal murine spleen cells with 
allogeneic nonproducer leukemia cells, produces a subpopulation of lymphocytes 
with syngeneic tumor-specific cytotoxicity. The antigen reactivity of these cyto- 
toxic lymphocytes may be directed against tumor-associated cell surface anti- 
gens (TASA) not necessarily related to viral antigens. 
Materials  and  Methods 
Mice.  Age-matched adult females, C57BL/6 and DBA/2, 5- to 7-wk-old were used in immuniza- 
tion experiments. Adult females from each strain (5- to 10-wk-old) were used as sources of normal 
spleen, lymph node, and thymus cells. All mice were obtained from The Jackson Laboratory, Bar 
Harbor,  Maine. 
Tumor Cells.  Cells  used for immunization and in MTLC  were  F4-5,  a  nonvirus producing 
subclone of F-4, syngeneic to the DBA/2 mouse, (obtained from Dr. W. Ostertag of the Max Planck 
Institute,  GSttingen, Germany),  and FBL-3(Hn)  a  nonvirus-producing cell line syngeneic to  the 
C57BL/6. Both cell lines were originally induced by Friend leukemia virus (FLV). FBL-3(Hn) was 
derived from the FBL-3 leukemia cell  (originally obtained from Dr.  Ronald Herberman of the 
National Cancer Institute) by adaptation of ascites-passaged FBL-3 cells to  long-term in vitro 
culture in our laboratory.  Unlike FBL-3,  FBL-3(Hn) does not generate a  regressing tumor after 
subcutaneous inoculation  in syngeneic mice. In fact,  subcutaneous injection  of as few as 102 live 
FBL-3(Hn) cells  produces a progressively  growing, lethal  tumor. Tumor cells  used as targets in 
cytotoxicity  assays included FBL-3(Hn), F4-5,  the P815 mastocytoma cell  (obtained from Dr. H. R. 
MacDonald, Ontario Cancer Research Institute,  London, Ontario, Canada), and the FLV-induced 
FLD-3  (obtained from Dr.  W.  Ostertag) both syngeneic  to the DBA/2.  Other tumor targets 
included the Rauscher leukemia virus (RLV)-induced RBL-5 and the chemically-induced  EL-4 
(Gross virus negative) both syngeneic to the C57BL/6 mouse (both obtained from Dr. R. Herber- 
man). All cells  were maintained in  continuous culture  in  vitro  at  37°C in  a humidified atmosphere 
of  5% CO2 in air. 
Immunization.  Mice were immunized subcutaneously in  the right  flank with 5 × 10  e  mitomy- 
cin-treated  (15)  (100  ~g/ml) allogeneic  nonproducer leukemia cells  once a  week for  a period  of  6  wk. 
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Assays  for  Viral  Characterization  of Tumor  Cells.  All  tumor  cells  were  subjected  to  the 
following assays: 
X-C ASSAY FOR PRODUCTION OF MATURE MULV.  The method used was exactly as previously de- 
scribed (16) with the exception that the SC-1 cell line (17) was used as the primary cell inoculated 
by virus.  Samples for inoculation were prepared by sampling 24  h  tissue culture medium from 
tumor  cells  in  their  exponential  growth  phase.  By  inoculating multiple  tissue  culture  cluster 
wells (no. 3506,  Costar,  Data Packing Corp.,  Cambridge, Mass.) with log2 or loglo dilutions of the 
original tumor cell culture supernate, the amount of infectious MuLV produced was quantitated 
in terms of plaque-forming units/milliliter of tumor cell tissue culture superuate. 
ASSAY FOR REVERSE TRANSCRIPTASE  (RT)  ACTIVITY OF TUMOR TMUE  CULTURE  MEDIA.  Tissue cul- 
ture medium exposed for 24 h  to tumor cells in their exponential growth phase was harvested for 
testing. The RT activity assay was conducted as previously described (18).  A positive test for RT 
activity was indicated by high [ZH]thymidine-5'-triphosphate ([3H]TTP)  incorporation into the 
oligo dT poly rA primer template aliquot as opposed to  [3H]TTP incorporation into the oligo dT 
poly dA primer template aliquot. Positive control tests were conducted by using no. 8203-01 RNA 
directed DNA polymerase purified from RLV peak fraction (Litton Bionetics, Bethesda, Md.). 
COMPLEMENT-MEDIATED ANTIBODY-DEPENDENT CYTOLYSIS.  Tumor cells used as targets in LMC 
(Cr-relRse) assays were tested for the presence of cell surface viral proteins by using antisera oh- 
mined from  Dr.  Jack  Gruber  (Office of Program  Resources  and Logistics,  Viral  Oncology,  Na- 
tional Cancer Institute,  Bethesda,  Md.).  Absorbed goat antisera to  gp-71,  p-30,  and p-12  (RLV) 
were  tested.  Tumor cells were  labeled with 250  ~Ci of Na~ 51CrO4 (sp  act  100-400  mCi/mg Cr), 
(Amersham/Searle Corp.,  Arlington Heights,  Ill.).  The target cell concentration was adjusted in 
RPMI 1640  (Grand Island Biological Co.,  Grand Island, N.Y.)  with 10% fetal calf serum (FCS) to 
0.1  counts per minute (cpm)/cell. Target cells were distributed in multiple 100-~1  volumes to in- 
dividual  wells  of V-bottom microplates  (no.  1S-MVC-96-TC,  Linbro Chemical  Co.,  New  Haven, 
Conn.).  Log2 dilutions of each antisera were added in 50-~1  aliquots to multiple microplate wells 
containing the target cell  suspension.  Atter  a  30-rain,  37°C  incubation,  50  ~1  of absorbed  (19) 
rabbit complement (Gibco Diagnostics, The Mogul Corp.,  Chagrin Fall,  Ohio) was added to each 
well containing either medium, ZAP Isoton Solution ([three drops added to 5 ml of double distilled 
water],  [Coulter Electronics Inc., Hialeah, FIR.l),  or a  dilution of specific antisera and the reaction 
was  allowed  to  continue  for  an  additional  90  min  incubation  at  37°C.  Chromium  release  was 
terminated by a  400 g  centrifugation at 4°C.  Supernate  (100  ~1) was removed and counted in 3.5 
ml  of Biofluor  Scintillant Fluid  (NEF  961,  New  England  Nuclear,  Boston,  Mass.)  by  a  liquid 
scintillation counter. Percent cytotoxicity was calculated according to the following equation. 
cpm experimental -  cpm complement +  target cell control 
Percent cytotoxicity :  ×  100 
cpm maximum -  cpm complement + target cell control 
Target  cell  surface  density  of particular  viral antigens  was  expressed  by the  highest titer of 
specific  antisera  necessary  to  cause  20%  complement-mediated  antibody-dependent lysis.  The 
absorbed complement rarely caused over 5% spontaneous lysis of the target cells. 
In Vitro Generation of Cytotoxic  Lymphocytes.  Spleen cells from immunized and/or normal 
mice were selected for use as responding cells in several in vitro culture treatments. Cells were 
teased apart from the intact organ with forceps, minced, and passed through successively smaller 
gage needles to ensure single cell suspensions. Erythrocytes were removed from the cell popula- 
tion by hypo-osmotic shock, and remaining cells were counted with an electronic Coulter Counter 
(Coulter Electronics). Aider determining viability via trypan blue exclusion, cells were diluted in 
Click's medium  (20)  (Altick  Associates,  Hudson,  Wis.)  supplemented with 300  ~g/ml fresh L- 
glutamine (Gibco  Diagnostics),  50 U/ml penicillin,  50 /~g/ml  streptomycin,  16 ~mol/ml NaHCO3, 
25 ftmol/ml HEPES buffer  (Gibco Diagnostics),  and 2% heat inactivated  FCS. Spleen  cell  popula- 
tions  were adjusted  to a final  concentration of  2.5 × i0  e  cells/ml. 
Primary MTLC  stimulation was conducted by mixing 10 ml of spleen cells  with 10 ml of 
mitomycin-treated  (100  /~g/ml)  nonproducer murine leukemia cells  which had been adjusted in 
supplemented Click's  medium to a concentration of 6.25 x  104 cells/ml.  Primary MTLC  were 
cultured upright in 30-ml tissue  culture flasks  (no.  3012,  Falcon Plastics,  Division of  BioQuest, 
Oxnard, Calif.)  in  an  humidified atmosphere  of  5% COx  in  air,  at  37°C.  Identical  culture  conditions 
were used for  primary mixed lymphocyte cultures  (MLC) except that a 1/1 ratio  of  responder to 
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proliferating  by a 1,500  rad X irradiation  (Cobalt  source).  Primary MTLC  (MLC) were harvested 
after  5 days in  culture  and viable  cells  were used as effector  ceils  in LMC  assays or subjected  to 
secondary  stimulation. 
Secondary MTLC  stimulations were conducted  by resuspending  responding lymphocytes from 
primary MTLC  flasks  in two 10-ml aliquots  of  fresh  supplemented Click's  medium and mixing 
each aliquot  with 10 ml of  mitomycin-treated nonproducer leukemia cells  (6.25 x 104 cells/ml). 
Similarly,  secondary  MLC stimulation  was  achieved  by  harvesting viable  cells  from  primary  MLC 
flasks,  and resuspending  them in 20 ml of  fresh  supplemented Click's  medium. This suspension 
was placed  in  new flasks  (i0  ml/flask)  with i0  ml of  X irradiated  (1,500  rad)  allogeneic  spleen  cells 
(2.5 x 10  ~  cells/ml).  Secondary Concanavalin A  ([Con A], [Miles-Yeda Laboratories,  Rehoveth, 
Israel])  stimulation  of  either  MTLC  or  MLC reactions  was  conducted  by resuspending  viable  cells 
harvested  from primary MTLC  (MLC) in  20  ml  of  fresh  supplemented  Click's  medium and adding 
to  each 10  ml aliquot  another 10  ml fresh  supplemented Click's  medium containing Con A (5/~g/ 
ml). 
All secondary stimulations (MLC, MTLC, or Con A) were conducted upright in 30-ml tissue 
culture flasks  in an humidified atmosphere of 5% COs in air at 37°C.  Secondary stimulation 
cultures  were terminated  two  days  after  their  initiation  and  viable  lymphocytes  harvested  for  use 
as effector  cells  in LMC  assays. 
LMC Assay.  Target  cells  were labeled  as described  above and distributed  in 100-/~I  volumes  to 
multiple V-bottom microplate wells. Effector  cells  were harvested from 5 day primary MTLC 
(MLC) or  2  day  secondary  MTLC  (MLC) and  adjusted  to  give  an  effector/target  cell  ratio  of  at  least 
50/1.  Logs dilutions  of  the effector  cells  were made and added to the targets  in 100-/~I  volumes. 
Each effector/target  cell  ratio  was repeated in replicate  microplate wells.  Microplates were then 
centrifuged  at  350  g for  10  min and  incubated  in  5% CO2 at  37°C for  hours.  The  51Cr  release  reaction 
was  stopped by  a 400g centrifugation  for  10  rain  at  4°C.  A 100-/~I  supernatant  aliquot  was  removed 
from each well, suspended in 3.5 ml of Biofluor Scintillant  Fluid, and counted on a liquid 
scintillation  counter,  cpm of  chromium release  from individual  medium, ZAP (maximum), and 
effector/target  cell  multiplicates  were averaged, and standard  deviation  and percent specific  lysis 
were calculated  with the aid of a basic computer program and the Dartmouth Time Sharing 
System. Percent specific  lysis  was determined  by using  the following  equation: 
Percent specific lysis =  100  x 
experimental cpm -  medium control cpm 
maximum release cpm -  medium control cpm 
Negative  values  were interpreted by the  computer  as  0%  specific lysis.  1  lytic  unit  (LU)  was 
defined as the number of effector cells required to cause 30% specific lysis. Data is displayed both 
graphically and in tabular form as percent cytotexicity observed at an effector/target cell ratio of 
100/1, and as LU/culture. In cases where 30% cytotoxicity was not achieved even at relatively high 
effector/target cell ratios, LU were determined by graphical interpolation. 
Results 
Virological Characterizations  of  Hemopoietic Tumor Cell Lines.  The results 
of tests for  virus production  and  cell  surface  viral  antigen  expression  of the 
tumor  cells  used,  appear  in  Table  I.  Tumor  cells,  syngeneic to  the  C57BL/6 
mouse included the RLV-induced RBL-5, which was confirmed in X-C and R-T 
assays as a  low titer  virus producer  and  which demonstrated  cell  membrane 
expression ofgp-7I. FBL-3(Hn) tested negative for MuLV production in X-C and 
R-T assays yet expressed gp-71 at the cell surface.  Supernates harvested from 
cultures of EL-4 (also syngeneic to the C57BL/6), were negative for virus produc- 
tion  and  the  cells  themselves  were  void  of cell  surface  expression  of viral 
antigens gp-71, p-30, or p-12. Cells tested in the DBA/2 histocompatibility model 
system  included  a  confirmed  virus  producing  line,  FLD-3,  whose  cell  mem- 
branes were positive for expression of gp-71 and p-30. The FLV-induced nonpro- 
ducer, F4-5 was also positive for gp-71. The P815 tumor cell tested negative for 472  CYTOTOXIC LYMPHOCYTES FROM REPETITIVE ALLOGENEIC MTLC 
TABLE  I 
Viral Characterizations  of Tumor Cells 
MuLV  Cell surface expression of  viral  anti- 
Cell  designa-  Host  Transforming agent  RT activity*  Produc-  gensll 
tion  mouse  tion~: 
GP-71  p-30  p-12 
RBL-5  C57BL/6  RLV  9,606/5,439  57,2  1/125  §  § 
FBL-3(Hn)  C57BL/6  FLV  1,606/1,502  0.0  1/640  §  § 
EL-4  C57BL/6  Benzanthracene  3,560/9.430  0.0  §  §  § 
FLD-3  DBA/2  FLV  387,454/16,988  1,818.0  1/320  1/320  § 
F4-5  DBA/2  FLV  1,392/5,665  0.0  1/50  §  § 
P815  DBA/2  Methylcholanthrene  57,575/52,893  0.0  §  §  § 
Purified RLV RT  58,139/6,570 
* Expressed in terms of cpm incorporation of [~H]thymidine-triphosphate by oligo dT poly rA template aliquot/cpm incorporation of 
13H]thymidine-triphosphate  by oligo dT poly dA template aliquot. 
* Expressed in terms of plaque-forming units/milliliter of tissue culture supernate  as determined by the X-C assay. 
§ No cell surface  expression of viral protein  by complement-mediated  antibody-dependent  cytotoxicity,  by using goat antisera 
produced against individual, purified RLV proteins. 
i/Expressed  in terms  of highest dilution  of specific antisera  yielding  20%  cytotoxicity  as  measured by  complement-mediated 
antibody-dependent-cytotexicity.  Goat antisera produced against RLV gp-71,  p-30,  and p-12. 
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EFFECTOR/TARGET CELL RATIO 
FIO.  i.  (A) Lysis of the allogeneic tumor cell target  F4-5 mediated by C57BL/6 lympho- 
cytes subjected to a single  allogeneic  MTLC activation with F4-5 (O--O)  and by C57BL/6 
effector cells harvested after secondary allogeneic MTLC with F4-5 (A--A). (B) Lysis of the 
allogeneic tumor target cell FBL-3(Hn) effected by DBA/2 lymphocytes subjected to a single 
allogeneic MTLC activation with FBL-3(Hn) (O--O)  and by DBA/2 lymphocytes harvested 
after secondary allogeneic MTLC activation with FBL-3(Hn) (A--A). 
virus production by X-C and R-T assays and negative for cell surface expression 
of viral proteins gp-71,  p-30 and p-12. 
Secondary Allogeneic MTLC. 
ELEVATION  OF  CYTOTOXICITY  DIRECTED  AGAINST  ALLOGENEIC  TUMOR  TAR- 
GETS.  Allogeneic  tumor  cell  lysis  by effector  cells  generated  in primary and 
secondary  allogeneic  MTLC  is  displayed  in  Fig.  1.  LMC  directed  toward the 
same allogeneic target cell which had been used as the MTLC stimulating agent 
dramatically  increased  when  a  secondary  allogeneic  MTLC  activation  was 
performed on cells surviving a primary allogeneic MTLC. This phenomenon was 
observed in both the C57BL/6 and DBA/2 model systems. Allogeneic cytotoxicity STEVEN  GILLIS  AND  KENDALL  A.  SMITH 
TABLE  U 
Lysis of Syngeneic Tumor Cell Targets by MTLC Effector Cells 
473 
Source of  Primary  Secondary 
spleen  stimulation  stimulation 
cells 
Syngeneic tumor cell cytotoxicity 
FBL-3(Hn)  RBL-5  EL-4 
C57BL/6  F4-5(A-MTLC)*  -  1% (6.7)  3% (11.2)  0% (0.0) 
C57BL/6  F4-5(A-MTLC)  F4-5(A-MTLC)  31% (255.1)  37% (454.5)  18% (81.2) 
C57BL/6  FBL-3(S-MTLC)*  FBL-3(S-MTLC)  0% (0.0)  0% (0.0)  0% (0.0) 
C57BL/6  DBAX(A-MLC)§  -  3% (8.9)  5% (17.5)  0% (0.0) 
C57BL/6  DBAx(A-MLC)  DBA~(A-MLC)  7% (16.7)  6% (12.5)  0% (0.0) 
FLD-3  F4-5  P815 
DBA/2  FBL-3(A-MTLC)  -  0% (0.0)  0% (0.0)  0% (0.0) 
DBA/2  FBL-3(A-MTLC)  FBL-3(A-MTLC)  43% (862.1)  41% (531.1)  38% (454.5) 
DBA/2  F4-5(S-MTLC)  F4-5(S-MTLC)  1% (6.2)  0% (0.0)  3% (9.2) 
DBA/2  C57BL/6x(A-MLC)  -  3% (5.1)  0%  (0.0)  1%  (i.I) 
DBA/2  C57BL/6x(A-MLC)  C57BL/6x(A-MLC)  5% (7.1)  0% (0.0)  7% (9.8) 
* A, allogeneic. 
* S, syngeneic. 
§ DBA  X or C57BL/6  x refers to  irradiated populations of respective spleen cells.  Cytotoxicity is 
expressed in terms of lysis at an effector to target ratio of 100:1 and in LU per culture, e.g. 75% 
(5432.7). 
demonstrated  against  F4-5 was 25%  (208 LU/culture) at an effector/target cell 
ratio of 100/1 after primary allogeneic MTLC stimulation.  Cytotoxicity rose to 
almost  100%  (25,000  LU/culture)  at  a  similar  ratio,  after a  second allogeneic 
MTLC activation.  DBA/2 spleen cells stimulated in primary allogeneic MTLC 
with FBL-3(Hn) generated lymphocytes only 13% cytotoxic to FBL-3(Hn) cells 
(55 LU/culture) at an effector/target cell ratio of 100/1. Spleen cells subjected to 
secondary  allogeneic  stimulation  demonstrated  92%  cytotoxicity  (25,000  LU 
culture) at the same effector/target cell ratio.  Similar high levels of allogeneic 
tumor cell lysis were also observed when lymphocytes from secondary allogeneic 
MTLC were tested against other allogeneic tumor cell targets  (Table III). 
DEMONSTRATION  OF SYNGENEIC TUMOR  CELL LYSIS.  Cytotoxic cells capable of 
mediating syngeneic tumor cell lysis were generated only after a secondary allo- 
geneic  MTLC.  This  phenomenon  was observed both in  cases where  C57BL/6 
spleen cells were stimulated twice in vitro with allogeneic F4-5 tumor cells and 
when DBA/2 normal spleen cells were activated twice by FBL-3(Hn) cells. Syn- 
geneic tumor cell lysis is represented both in terms of LU/culture and percentage 
of target cells lysed at an effector/target cell ratio of 100/1  (Table II).  Several 
MTLC and MLC combinations were tested to determine if other in vitro stimula- 
tions  would  be  as  effective in  generating  lymphocytes capable  of mediating 
syngeneic tumor  cell  lysis.  Cells harvested  from  either  a  primary  allogeneic 
MTLC  or primary  MLC were not cytotoxic to syngeneic tumor cells.  Effector 
cells generated from secondary allogeneic MLC and secondary syngeneic MTLC 
(C57BL/6 spleen cells activated twice with mitomycin-treated FBL-3(Hn) cells 
and conversely DBA/2 spleen cells stimulated twice in vitro with F4-5 cells), did 
not demonstrate eytotoxicity directed against syngeneic tumor cell targets. 
SPECIFICITY OF SYNGENEIC  TUMOR CELL CYTOTOXICITY.  After the observation 474  CYTOTOXIC 
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EFFECTOR/TARGET  CELL RATIO 
FIO.  2.  (A) Lysis of the syngeneic tumor target cell FBL-3(Hn) (I--I)  by C57BL/6 spleen 
cells harvested from secondary allogeneic MTLC  stimulation with F4-5.  Each line repre- 
sents one of a  number of repetitive experimental trials.  Cytotoxicity mediated by these 
same effector cells against syngeneic normal lymph node (A--Z~), thymus (©--©), and Con 
A stimulated spleen cells ([~--F-1) is also depicted. (B) Lysis of the syngeneic tumor cell F4-5 
(m--B) demonstrated by DBA/2 lymphocytes harvested from secondary allogeneic MTLC 
activation with FBL-3(Hn). No cytotoxicity is mediated by these same effector cells against 
DBA/2 lymph node (A--A), thymus (©--©), and Con A stimulated spleen cells (D--D). 
that secondary allogeneic MTLC stimulation of normal spleen cells led to pro- 
liferative generation of lymphocytes capable of effecting syngeneic tumor cell 
lysis, experiments were designed to test whether or not this lysis was directed 
solely against syngeneic tumor cell targets. Results of these experiments are 
represented graphically in Fig. 2. C57BL/6 spleen cells stimulated twice in al- 
logeneic MTLC with F4-5 were cytotoxic to FBL-3(Hn) Friend leukemia cells yet 
were not cytotoxic to either syngeneic normal lymph node, thymus, or spleen 
cells stimulated 2 days previously with Con A  (2.5 ~g/ml). DBA/2 lymphocytes 
generated in secondary allogeneic MTLC with FBL-3(Hn) were highly cytotoxic 
to syngeneic F4-5 Friend leukemia cells yet were not cytotoxic to DBA/2 lymph 
node, thymus, and Con A-stimulated spleen cells. 
Secondary allogeneic MTLC in both the DBA/2 and C57BL/6 histocompatibil- 
ity model systems were repeated and the effector cells generated, were retested 
for their cytotoxic potential against other syngeneic tumor cell targets. Results 
of these repetitive trials are displayed graphically in Figs. 2 and 3 and in tabular 
form in Table II. Syngeneic tumor cell lysis was not dependent upon target cell 
production of infectious MuLV, or upon cell surface expression of RNA tumor 
virus structural proteins. In the C57BL/6 model system, cytotoxicity was demon- 
strated against both the low titer virus-producing tumor cell, RBL-5,  and the 
nonproducer FBL-3(Hn) (whose membranes expressed gp-71),  as well as against 
a  nonproducer whose  cell  surfaces lacked detectable  concentrations of viral 
antigens (EL-4). DBA/2 tumor targets were also lysed equally well by syngeneic >- 
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EFFECTORITARGET  CELL RATIO 
(A) Lysis  of other syngeneic  tumor cells effected  by C57BL/6 spleen cells after 
secondary allogeneic MTLC activation. Cytotoxicity  is directed against the FLV-induced 
nonproducer leukemia  cells  FBL-3(Hn) (D--D), the RLV-induced  virus-producing  leukemia 
cell RBL-5 (O--O), and the chemically-induced  (Gross virus negative) EL-4 (A--A). (B) 
DBA/2 lymphocytes  selected by secondary  allogeneic  MTLC  and assayed  for their cytotoxic 
potential against syngeneic  FLV-induced  nonproducer  F4-5 cells (Z]--O), FLV-induced  high 
titer virus producing FLD-3 cells (O--O), and chemically-induced  P815 cells (/X--A). 
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effector cells generated in secondary allogeneic MTLC regardless of whether or 
not they produced MuLV or expressed viral structural proteins  on their cell 
surfaces. All effector cells which demonstrated syngeneic tumor-specific cytotox- 
icity  were  sensitive  to  lysis  with  anti-theta  serum  ([mouse  AKR-anti-C3H 
ascites]  [no.  8301, Bionetics Laboratory Products,  Kensington, Md.])  and ab- 
sorbed rabbit complement. 
Secondary Stimulation with Con A.  Further experimentation was designed 
to discover why secondary allogeneic MTLC stimulation of normal spleen cells 
was successful in generating syngeneic tumor-specific cytotoxic lymphocytes, 
whereas secondary MLC and primary allogeneic MTLC were not.  It seemed 
possible that secondary allogeneic MTLC activation might act as a nonspecific 
restimulator of a  small population of cytotoxic cells to proliferate to the point 
where they were capable of demonstrating cytotoxicity against syngeneic tumor 
cell  targets.  To  test  this  hypothesis  experiments  were  conducted  in  which 
normal spleen cells, subjected to a single allogeneic MTLC, were harvested and 
restimulated with Con A (2.5 ~g/ml), for an additional 2 days, after which they 
were tested for cytotoxicity  against both syngeneic and allogeneic tumor cells. In 
addition, viable cells harvested from primary MLC stimulation were restimu- 
lated with Con A and tested for their cytotoxic specificities. Other effector cell 
populations included viable cells harvested from secondary allogeneic MTLC 
stimulation, and normal spleen cells stimulated with Con A (2.5 ~g/ml) for 48 h 
before their use in cytotoxicity assays. Results of these experiments are dis- 476  CYTOTOXIC  LYMPHOCYTES  FROM  REPETITIVE  ALLOGENEIC  MTLC 
TABLE  III 
Secondary Stimulation  with Con A Lysis of Tumor Cell Targets 
Source 
of  Primary 
spleen  stimulation 
cells 
C57BL/6  F4.5(A-MTLC)* 
C57BL/6  F4-5(A-MTLC) 
C57BL/6  CON A 
C57BL/6  DBA/2x§(A-MLC) 
C57BL/6  DBA/2x(A-MLC) 
DBA/2  FBL-3(A-MTLC) 
DBA/2  FBL-3(A-MTLC) 
DBA/2  CON A 
DBA/2  C57BL/6z(A-MLC) 
DBA/2  C57BL/6x(A-MLC) 
* A, allogeneic. 
Secondary 
stimulation 
F4-5(A-MTLC) 
CON  AS 
CON A 
DBA/2x(A-MLC) 
FBL-3(A*MTLC) 
CON A 
CON A 
C57BL/6" (A-MLC) 
FLD-3 
93% (25,000) 
81% (12,000) 
0% (0.0) 
9% (3.1) 
79% (25,000) 
29% (285.11) 
9% (4.0) 
0% (0.0) 
0% (0.0) 
5% (7.1) 
F4-5 
97% (25,000) 
49% (1,470) 
0% (0.0) 
0% (0.0) 
44% (862.0) 
36% (329.2) 
12% (20.8) 
0% (0.0) 
0% (0.0) 
0% (0.0) 
P815  FBL-3(Hn)  RBL-5 
94% (14,705)  29% (295.4) 
71% (3,571) 
18% (5.6) 
94% (11,363) 
28% (275.1) 
8% (25.0) 
0% (0.0) 
7% (11.7) 
EL-4 
34% (313.2)  16% (90.7) 
0% (0.0)  0% (0.0)  0% (0.0) 
0% (0.0) 
0% (0.0)  0% (0.0)  0% (0.0) 
5% (7.1)  0% (0.0)  7% (11.1) 
92% (25,000)  75% (25,000)  32% (263.1) 
77% (20,633)  68% (8,333)  20% (62.5) 
0% (0.O) 
25% (166.7)  23% (1542)  0% (0.0) 
86% (25,000)  56% (12,000)  20% (83.3) 
CON  A refers  to  secondary stimulation with the mitogen Con A at a concentration of  2.5 ~.g/ml. 
§ DBA/2  x  or C57BL/6 refers  to irradiated  populations of  respective  spleen cells,  Cytotoxicity  is  expressed in  terms of  lysis  at an effector  to 
target  cell  ratio  of  100:1  and in LU per culture,  e.g.,  75% (5432.7). 
played  in  Table  III.  Only  cells  harvested  from  secondary  allogeneic  MTLC 
stimulation  were  capable  of  effecting  syngeneic  tumor-specific  cytotoxicity. 
Cells harvested from primary allogeneic  MTLC and secondary Con A  stimula- 
tion lysed only allogeneic targets.  Spleen cells harvested from primary alloge- 
neic  MLC  activation  and  restimulated  nonspecifically  with  Con  A  were  not 
cytotoxic to syngeneic  tumor cells.  Normal spleen cells stimulated solely with 
Con A  demonstrated  neither syngeneic  nor allogeneic  tumor cell  cytotoxicity. 
According to these results  (Table III), it appeared that the stimulus present in 
secondary allogeneic  MTLC conditions which allowed for generation of tumor- 
specific  cytotoxic  lymphocytes  was  a  specific-antigen  stimulation  which  could 
not be mimicked by mitogen-induced proliferation. 
Primary and Secondary Allogeneic MTLC Stimulation of Spleen Cells from 
Mice Immunized  with Allogeneic Nonproducer Friend Leukemia  Cells.  We 
questioned whether spleen cells from mice immunized with mitomycin-treated 
allogeneic Friend leukemia cells and activated in vitro via primary or secondary 
allogeneic  MTLC  would  be  as  effective  in  demonstrating  syngeneic  tumor- 
specific cytotoxicity,  as were normal spleen cells subjected to secondary alloge- 
neic MTLC. 5- to 7-wk-old normal C57BL/6 female mice were immunized weekly 
with a subcutaneous inoculum of 5  ×  106 mitomycin-treated allogeneic nonpro- 
ducer  Friend  leukemia  cells  (F4-5).  Mice  were  immunized  six  times.  Age- 
matched DBA/2 female mice were immunized by using an identical immuniza- 
tion  schedule  and  route,  with  5  ×  106  mitomycin-treated  FBL-3(Hn)  Friend 
leukemia cells.  2-4 wk after final immunizations,  spleen cells  were harvested 
from  immunized  mice  and  stimulated  in  allogeneic  MTLC  reactions.  After 
MTLC  stimulation  viable  cells  were  assayed  for cytotoxicity  directed  against 
allogeneic and syngeneic tumor cell and syngeneic normal cell targets.  Results 
of experiments involving spleen cells taken from C57BL/6 mice immunized with 
F4-5 are displayed in tabular form (Table IV). 
Spleen cells taken from C57BL/6 mice immunized with F4-5 and activated in 
vitro in a  primary allogeneic  MTLC were effective  in killing  syngeneic  tumor 
cells. Tumor targets lysed included the same FBL-3(Hn), RBL-5, and EL-4 cells 
used  as  targets  in  earlier  LMC  assays  (Fig.  3 A,  Table  III).  The  amount  of STEVEN  GILLIS  AND  KENDALL  A.  SMITH 
TABLE IV 
Secondary Stimulation of Immune Spleen Cells: Lysis of Tumor Cell Targets 
Source of  Primary  Secondary  FLD-3 
spleen cells  stimulation  stimulation 
F4-5(A-MTLC)  C57BI.J6 
C57BL/6 im. 
munized 
with F4-5 
C57BL/6 ira. 
munized 
with F4-5 
C57BL/6  ira. 
munized 
with F4-5 
F4-5(A-MTLC)* 
?4-5(A-MTLC) 
F4-5(A-MTLC)  F4-5(A-MTLC) 
96%(25,000) 
95%(25,000) 
90%(25,000) 
0%(0.0) 
Cytotoxicity is expressed in terms of lysis at an effector  to tar 
* A, allogeneic. 
F4-5  P815 
92% (25,000)  89% (15,750) 
35% (25.000)  90% (12,195) 
98% (25,000) 
0% (0.O) 
87% (11,905) 
0% (0.0) 
FBL-3(Hn)  RBL-5 
31% (255,1)  37% (454.5) 
33% (265.9)  24% (175.2) 
39% (367.64)  29% (226.5) 
0% (0.0)  0% (0.0) 
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EL-4 
18% (31.2) 
17% (113.4) 
15% (92.2) 
0% (0.O) 
et cell  ratio  of I00:i and in LU per culture, e.g..  75% (5432.7). 
syngeneic tumor cell  lysis  observed was  comparable to  that  observed after 
secondary allogeneic stimulation of normal spleen cells. Therefore regardless of 
whether the first allogeneic stimulation was given in vitro or in vivo, secondary 
allogeneic activation was shown to be capable of producing effector cells which 
displayed syngeneic tumor-specific cytotoxicity. 
Because of this observation, we questioned whether further allogeneic stimu- 
lation would produce lymphocytes which expressed greater levels of syngeneic 
tumor-specific cytotoxicity. Experiments were conducted which subjected lym- 
phocytes, harvested from mice immunized with allogeneic nonproducer leuke- 
mia cells, to secondary allogeneic MTLC stimulation (essentially tertiary allo- 
geneic stimulation). Results of these experiments are shown in Table IV.  The 
data collected showed that tertiary allogeneic MTLC  stimulation of F4-5 im- 
mune cells did not create a  population of cells which demonstrated greater 
syngeneic tumor-specific cytotoxicity than that already present after a second- 
ary allogeneic MTLC.  Furthermore, cytotoxicity was  not  greater than that 
effected by  normal  C57BL/6 spleen  cells  subjected to  secondary allogeneic 
MTLC.  Similar results were obtained with lymphocytes harvested from DBA/2 
mice  immunized with  allogeneic FBL-3(Hn)  cells  and  activated in  vitro  in 
primary and secondary MTLC. All effector cells which demonstrated syngeneic 
tumor-specific lysis were sensitive to lysis with anti-theta serum and comple- 
ment. 
Discussion 
Results of experimentation conducted in this study may be explained by the 
following hypothesis: successive MTLC stimulation of a normal lymphoid popu- 
lation leads to the selective proliferation of any number of subpopulations of 
antigen-specific lymphocytes. Because the antigen stimulation in these repeti- 
tive MTLC came from allogeneic nonproducer leukemia cells (which expressed 
the cell surface viral structural glycoprotein gp-71), a subpopulation of cytotoxic 
lymphocytes that one would expect to proliferate, would be cells with specifici- 
ties directed against differing histocompatibility antigens.  It is possible that 
different lymphoid subpopulations would be activated by other antigens present 
on the surface of the stimulating tumor cells. Our evidence indicates these other 
antigens are TASA which may be distinct from viral antigens. Because TASA(s) 478  CYTOTOXIC  LYMPHOCYTES  FROM  REPETITIVE  ALLOGENEIC  MTLC 
are presumably shared by all tumor targets, (including total nonproducers), it 
may be these TASA-reactive lymphocytes which are responsible for producing 
the syngeneic tumor-specific cytotoxicity observed in LMC assays. We believe 
that the antigen recognized is a  TASA rather than a  viral structural protein 
because the syngeneic tumor target cells lysed by spleen cells harvested from 
secondary allogeneic MTLC, include chemically, as well as virus-induced tumor 
cells and also include tumor cells which do not actively product infectious MuLV 
or express detectable cell surface concentrations of viral structural antigens (gp- 
71, p-30,  or p-12). 
Objections might  still  be  raised to  claiming that  the  antigen-reactivity of 
these  tumor-specific cytotoxic lymphocytes is  directed  against  a  TASA  not 
necessarily of viral  origin.  For one, this  study's viro'iogic characterization of 
tumor cell surface viral  antigen expression was  conducted by using antisera 
directed against  purified  RLV  antigens,  when  several  of the  tumor  targets 
tested were FLV-induced. However, this study (Table I) and others have demon- 
strated the type-specific cross-reactivity of antisera directed against structural 
antigens purified from either RLV or FLV (21,  22). It may also seem possible 
that antigen-reactivity might be directed against a viral structural protein, not 
assayed for cell surface expression (i.e., p-10 or p-15). Recent studies have shown 
that  p-10  and  p-12  are  totally  cross-reactive  as  determined by  quantitative 
competitive  radioimmunoassay  (23). Hunsmann  et  al.  have  further  demon- 
strated that p-15 is not expressed at the cell surface of several murine leukemia 
cells  and  that  the  only  viral  antigens  present  on  the  cell  surface  are  the 
structural glycoprotein gp-71  and the structural proteins,  p-30  and p-12  (24). 
Similar  observations  have  recently been  noted  in  studies  conducted in  our 
laboratory involving 15 murine leukemia cell lines maintained in continuous 
culture  (Smith,  K.  A.,  M.  M.  Ferm,  and A.  E.  Gillis,  unpublished observa- 
tions). 
It might also seem possible that the TASA responsible for the reactivity of the 
tumor-specific cytotoxic lymphocyte produced in  secondary allogeneic MTLC 
was  associated with either an endogenous or a  xenotropic RNA tumor virus 
produced in all tumor targets.  Although we have not directly tested for this 
possibility, the lack of RT activity (Table I) in culture medium, sampled from 
nonproducer tumor cell cultures lends evidence that this is not the case. 
Regardless of the antigen-specific reactivity of the syngeneic tumor-specific 
cytotoxic lymphocytes produced in  these studies,  one  must consider possible 
explanations as to why they are produced only via successive allogeneic MTLC 
stimulation. A simplistic explanation would be that only after two stimulations 
have tumor-specific cytotoxic lymphocytes proliferated to the extent where they 
are detectable in LMC assays. Other experiments conducted in this study point 
out the  problem with  this  hypothesis.  If secondary MTLC  stimulation  were 
solely a nonspecific proliferative stimulus, one would expect secondary stimula- 
tion  (of cells harvested from primary allogeneic MTLC)  with Con A  to have 
generated effector cells capable of lysing syngeneic tumor targets. However, this 
was not the case (Table III). Furthermore, because the antigen(s) recognized by 
these cytotoxic lymphocytes are presumably shared by syngeneic murine leuke- 
mia cells as well, one would expect secondary syngeneic MTLC stimulation to 
have produced lymphocytes capable of killing syngeneic tumor cells. However, STEVEN  GILLIS  AND  KENDALL  A.  SMITH  479 
experimentation (Table II) showed that secondary syngeneic MTLC activation 
of normal spleen cells was incapable of producing tumor-specific cytotoxic lym- 
phocytes. 
An appealing explanation is that the recognition of differing H-2 antigens (in 
secondary allogeneic MTLC) and the proliferation of anti-H-2 reactive lympho- 
cytes, produces a factor or a culture condition which stimulates the proliferation 
of other antigen-specific cytotoxic lymphocytes. In other words, repeated alloge- 
neic MTLC  stimulation produces a  cell-mediated allogeneic effect which may 
specifically aid in the generation of syngeneic tumor-specific cytotoxic lympho- 
cytes. The allogeneic effect, wherein induction of a graft versus host reaction in 
an antigen primed animal,  greatly enhances production of specific antibody 
after secondary antigen stimulation, has been associated with the generation of 
a soluble allogeneic effect factor (25, 26). Dutton et al. showed that supernates 
harvested from short-term in vitro cultures of histoincompatible mouse spleen 
cells contained a  nonantigen-specific, biologically active mediator, capable of 
markedly enhacing in vitro antibody responses to thymus-dependent antigens 
(27).  The  effects of similarly produced factors  have  been  incorporated into 
theories regarding T-  and  B-cell  cooperation  (28, 29). Other  soluble  factors 
produced by incubation of T cells with specific antigens (30) (other than those 
associated with the major histocompatibility complex) or with nonspecific mito- 
gens (31), have been successful in mediating T- and B-cell collaboration. 
Recently, a cell-mediated allogeneic effect has been documented in vitro in 
studies dealing with immune reactivity to human leukemia (32). With a three 
cell mix approach,  lymphocytes harvested from a  patient in remission from 
acute myelogenous leukemia were cocultured with autologous (previously har- 
vested) irradiated leukemia cells and irradiated allogeneic peripheral blood 
lymphocytes. Effector cells harvested from three cell mix cultures contained 
lymphocytes specifically cytotoxic to the patient's autologous leukemia cells. 
Effector cells harvested from cultures containing only remission lymphocytes 
and irradiated autologous leukemia cells were incapable of demonstrating au- 
tologous leukemia cell cytotoxicity. It was suggested that the success of the 
three cell mix in generation of leukemia-specific  cytotoxic lymphocytes was due 
to  a  strong proliferation-inducing stimulus  (in this case from the allogeneic 
irradiated lymphocytes) which when produced, stimulated other cytotoxic lym- 
phocytes. These findings are compatible with the concept of an allogeneic effect. 
A  similar effect may be  operating in  the  production of syngeneic tumor- 
specific cytotoxic lymphocytes via secondary allogeneic MTLC stimulation. The 
allogeneic nonproducer leukemia cell (used as the MTLC sensitizing agent) is at 
once the source for the production of allogeneic effect stimulation (in that it 
carries differing H-2  antigens for induction of a  large anti-H-2 proliferative 
response) and the source for presentation of tumor-associated antigens. These 
are the antigens recognized by the lymphocyte subpopulation which benefits 
from the allogeneic effect, and later expresses its reactivity against syngeneic 
tumor cells also bearing TASA(s). 
Such an allogeneic effect would explain why other culture treatments were 
incapable of generating tumor-specific cytotoxic tymphocytes. Secondary synge- 
neic MTLC  stimulation clearly would have been incapable of producing any 
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shared histocompatibility antigens. Any MLC stimulation would be unsuccess- 
ful because the normal lymphocytes used as stimulators lacked TASA(s).  Pri- 
mary allogeneic MTLC either alone or followed by secondary Con A stimulation 
may not generate enough of an allogeneic effect to successfully promote prolifer- 
ation of TASA-reactive lymphocytes. 
Finally, the procedure of secondary allogeneic MTLC may provide a means of 
detecting human leukemia associated antigens as  well as  defining whether 
cross-reactive human leukemia antigens exist. These are important questions 
since active immunotherapy with irradiated allogeneic leukemia cells is cur- 
rently under clinical investigation. Taylor et al. have reported negative studies 
in acute myelogenous leukemia where attempts were made to generate lympho- 
cytes cytotoxic to autologous leukemia cells aider a single allogeneic MTLC (33). 
Based upon results detailed in this report, it might be expected that a secondary 
MTLC stimulation would improve the sensitivity of these assays. 
Summary 
In  vivo  or  in  vitro  immunity to  murine leukemia virus  (MuLV)-induced 
leukemia cells which do  not  effectively produce virus,  has  been difficult to 
demonstrate. Because immunizations with allogeneic murine leukemia cells 
have been used to confer syngeneic tumor immunity  to virus-producing cells, we 
attempted to generate lymphocytes, cytotoxic to syngeneic nonproducer leuke- 
mia cells, by stimulating normal murine spleen cells with allogeneic nonpro- 
ducer leukemia cells in mixed tumor lymphocyte culture (MTLC) reactions in 
vitro.  Secondary allogeneic MTLC  of normal C57BL/6 or DBA/2  spleen cells 
effectively produced  syngeneic tumor-specific cytotoxic lymphocytes.  Target 
cells  lysed  in  lymphocyte-mediated cytolysis  (LMC)  assays,  included  both 
Friend and Rauscher virus-induced syngeneic murine leukemia cells and chemi- 
cally-induced hematopoietic tumor  cells.  Syngeneic tumor  cells  were  lysed 
regardless of whether they produced infectious MuLV or expressed viral anti- 
gens gp-71, p-30, or p-12 at the cell surface. Syngeneic normal cells (thymus, 
lymph node, or Concanavalin A-stimulated spleen cells) used as targets in LMC 
assays were uneffected by lymphocytes harvested from secondary allogeneic 
MTLC. Several other in vitro culture treatments including secondary syngeneic 
MTLC and repetitive mixed lymphocyte culture stimulations were incapable of 
generating tumor-specific cytotoxic lymphocytes. 
Based upon these results, we propose that secondary MTLC  stimulation of 
normal spleen cells with allogeneic nonproducer leukemia cells selects for the 
proliferation of two subpopulations of antigen-specific cytotoxic lymphocytes. 
The population capable of effecting syngeneic tumor cell lysis is directed against 
tumor-associated cell surface antigens which may be distinct from viral struc- 
tural proteins or glycoproteins. The growth of these tumor-specific cytotoxic 
lymphocytes may be enhanced by a soluble allogeneic effect factor produced by 
the proliferation of the second subpopulation of lymphocytes  generated in repeti- 
tive  allogeneic MTLC,  namely those lymphocytes with  specificities directed 
against differing histocompatibility antigens. 
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